Hosted by Ken Tupper, Intonicated is a podcast that explores how altered states of consciousness can function as tools for healing, learning and well-being. Drawing on decades of experience in public health, interdisciplinary education, and psychedelic research, Kenneth speaks with thinkers, practitioners, and storytellers shaping the future of this field. Intonicated is a neologism that contrasts with intoxicated, providing a term to denote the experience of being inwardly attuned, cognitively expanded, and oriented towards clarity, vitality and integration. If you’re curious about evidence, ideas, and insights that connect ancient wisdom with contemporary science, you’re in the right place. Subscribe for thoughtful, grounded dialogue about the frontiers of mind and meaning.
Intonicated
Claim This Podcastby Kenneth Tupper
Podcast Overview
Hosted by Ken Tupper, Intonicated is a podcast that explores how altered states of consciousness can function as tools for healing, learning and well-being. Drawing on decades of experience in public health, interdisciplinary education, and psychedelic research, Kenneth speaks with thinkers, practitioners, and storytellers shaping the future of this field. Intonicated is a neologism that contrasts with intoxicated, providing a term to denote the experience of being inwardly attuned, cognitively expanded, and oriented towards clarity, vitality and integration. If you’re curious about evidence, ideas, and insights that connect ancient wisdom with contemporary science, you’re in the right place. Subscribe for thoughtful, grounded dialogue about the frontiers of mind and meaning.
Language
🇺🇲
Publishing Since
1/15/2026
Reach the team behind Intonicated
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
June 30, 2026
Beyond Therapy: Why Psychedelics Matter for Public Health – A Conversation with Heather Kuiper
<p>In this episode of Intonicated, Kenneth speaks with Heather Kuiper, co-founder and Director of the Center for Psychedelic Public Health, about the emerging field of psychedelic public health and its potential to reshape how society understands these powerful substances.</p><p>Their conversation explores why psychedelics should be considered through a public health lens, not only as therapeutic tools for individuals, but as catalysts for community wellbeing, education, health promotion, and systems change. They discuss harm reduction, psychedelic exceptionalism, Indigenous knowledge and reciprocity, the importance of language, and how public health principles can help maximize benefits while minimizing harms.</p><p>Heather also shares the vision behind the Center for Psychedelic Public Health and its efforts to build a new interdisciplinary field that bridges research, policy, education, and community practice.</p><p>Whether you’re interested in psychedelics, public health, or the future of collective wellbeing, this conversation offers a thoughtful exploration of how these worlds can come together to support healthier people and communities.</p><p><strong>Time Stamps</strong></p><ul><li>0:53 – Introduction</li><li>2:08 – What Is Public Health?</li><li>4:32 – Why Psychedelics Need Public Health</li><li>6:49 – Research on Psychedelics in Schools of Public Health</li><li>10:33 – Building the Field of Psychedelic Public Health</li><li>13:39 – Harm Reduction and Psychedelics</li><li>17:59 – Psychedelic Exceptionalism</li><li>22:23 – Indigenous Principles in Psychedelic Public Health</li><li>26:41 – The Power of Language</li><li>31:38 – Psychedelics, Education & Consciousness</li><li>37:03 – Ritual vs. Recreation</li><li>39:30 – Building the Future of Psychedelic Public Health</li><li>47:30 – Final Thoughts</li></ul><br/><p><strong>Guest:</strong></p><p>Heather Kuiper, DrPH is Founder and Director of the Center for Psychedelic Public Health. A public health leader with expertise in health equity, environmental justice, and community wellbeing, she has led initiatives spanning maternal health, environmental health, and systems change. Her current work focuses on advancing psychedelic public health through global collaboration, Indigenous partnerships, and population-level approaches to health and wellbeing.</p><p><strong>Links:</strong></p><p><a href="https://www.psychedelicpublichealth.org/" rel="noopener noreferrer" target="_blank">https://www.psychedelicpublichealth.org/</a></p><p><a href="https://www.sciencedirect.com/science/article/pii/S0277953624005872 " rel="noopener noreferrer" target="_blank">https://www.sciencedirect.com/science/article/pii/S0277953624005872 </a></p><p><a href="https://www.cpha.ca/discussion-document-public-health-perspectives-future-psychedelics " rel="noopener noreferrer" target="_blank">https://www.cpha.ca/discussion-document-public-health-perspectives-future-psychedelics </a></p><p>https://realworldpsychedelics.com/</p><p><strong>Host: </strong></p><p>Kenneth Tupper is a public health researcher, drug policy expert, and educator whose work focuses on psychedelics, learning, and wellbeing.</p><p><strong>Disclaimer: </strong></p><p>This podcast is for informational and educational purposes only. It does not constitute medical advice. Psychedelics are powerful substances with known risks and are illegal in many jurisdictions. Always consult qualified medical professionals and follow applicable laws.</p>
May 16, 2026
Finding the Work: A Therapist’s Path into Psychedelics – A Conversation with Cody Callon
<p>In this episode of Intonicated, host Kenneth Tupper speaks with therapist Cody Callon about the evolving landscape of psychedelic-assisted therapy.</p><p>Cody shares his path from harm reduction work in Vancouver’s Downtown Eastside to becoming a clinician specializing in trauma and psychedelic therapies. He reflects on his first experiences with ayahuasca, the challenges of integration without community, and how these experiences gradually informed his professional direction.</p><p>The conversation explores key themes in contemporary psychedelic practice, including the role of preparation and integration, the importance of therapeutic alliance, and why these substances are better understood as tools rather than standalone cures. Cody also offers insights into matching different medicines to individual needs, emphasizing a personalized, trauma-informed approach.</p><p>They discuss real-world clinical experience with ketamine, MDMA, and psilocybin, alongside the practical and regulatory barriers to access in Canada—particularly through Health Canada’s Special Access Program.</p><p>The episode closes with a reflection on the paradox of limited therapeutic access despite increasing public availability, and what this means for the future of safe, effective psychedelic care.</p><p><strong>Time Stamps</strong></p><ul><li>01:09 – Introduction </li><li>02:21 – Social work career and drug policy interest</li><li>04:45 – Hearing about ayahuasca for first time </li><li>06:06 – Prior perception about psychedelics </li><li>07:36 – Learning about Gabor Mate’s work with ayahuasca and addiction treatment</li><li>10:19 – First time drinking ayahuasca </li><li>15:39 – Challenges with integration</li><li>19:38 – Getting opportunity to pursue psychedelic research</li><li>23:44 – Being trained to become a psychedelic therapist</li><li>26:18 – Early 2020s psychedelic bubble</li><li>30:44 – Getting experience offering ketamine- and MDMA-assisted therapy</li><li>34:24 – Patterned thinking and developmental trauma</li><li>38:54 – Preparation and integration support for clients</li><li>46:54 – Opportunities for greater access to psychedelic therapies</li><li>49:10 – Canada’s Special Access Program for psychedelics</li><li>53:46 – Mushroom dispensaries</li></ul><br/><p><strong>Guest:</strong></p><p>Cody Callon is a Vancouver-based therapist and registered social worker specializing in trauma, substance use, and psychedelic-assisted therapy. With nearly two decades of experience in mental health, harm reduction, and addictions research, he has worked in clinical, community, and research settings, including with the British Columbia Centre on Substance Use. Cody is trained in MDMA-, ketamine-, and psilocybin-assisted therapies and provides psychotherapy, psychedelic integration, education, and consulting services.</p><p><strong>Links:</strong></p><p><a href="https://www.codycallon.com" rel="noopener noreferrer" target="_blank">https://www.codycallon.com</a></p><p><a href="https://www.medicineassistedtherapy.ca" rel="noopener noreferrer" target="_blank">https://www.medicineassistedtherapy.ca</a> </p><p><a href="https://www.ciis.edu/continuing-education/center-for-psychedelic-therapies-and-research/about-the-certificate" rel="noopener noreferrer" target="_blank">https://www.ciis.edu/continuing-education/center-for-psychedelic-therapies-and-research/about-the-certificate</a> </p><p><a href="https://www.sabimind.com/blog/worldsfirstwellnesspsychedelicstudy" rel="noopener noreferrer" target="_blank">https://www.sabimind.com/blog/worldsfirstwellnesspsychedelicstudy</a> </p><p><strong>Host: </strong></p><p>Kenneth Tupper is a public health researcher, drug policy expert, and educator whose work focuses on psychedelics, learning, and wellbeing.</p><p><strong>Disclaimer: </strong></p><p>This podcast is for informational and educational purposes only. It does not constitute medical advice. Psychedelics are powerful substances with known risks and are illegal in many jurisdictions. Always consult qualified medical professionals and follow applicable laws.</p>
March 3, 2026
Sacred Synthetics: The Science and Soul of Psychedelic Pharmaceuticals – A Conversation with Danny Motyka
<p>In this episode of Intonicated, Kenneth Tupper sits down with Danny Motyka, co-founder and CEO of Psygen Industries, to explore what it means to manufacture psychedelics in an era of rapid cultural and regulatory change. </p><p>Drawing on his background in chemistry and early leadership in Canada’s medical cannabis industry, Danny traces his path into GMP psychedelic drug manufacturing and explains what “Good Manufacturing Practices” actually entail for compounds like psilocybin, MDMA, LSD, and ibogaine. The conversation moves beyond technical standards to examine deeper questions: What distinguishes synthetic from plant-derived medicines, not only chemically but experientially? Does a purified molecule carry the “spirit” of the plant? And when does a compound become a “medicine” in the eyes of the state?</p><p>Ken and Danny also grapple with reciprocity, biopiracy, and the ethical tensions surrounding ibogaine supply chains in Africa, as well as the broader commercialization of psychedelic therapies. From stigma and medical tourism to community-led access models and the future of FDA approvals, this episode offers a grounded, candid look at where the psychedelic field may be heading, and what kind of cultural transformation it might yet enable. </p><p><strong>Time Stamps</strong></p><ol><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>1:57 – Danny’s background and pathway to becoming CEO of Psygen</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>4:14 – What is GMP (Good Manufacturing Practices)?</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>7:49 – Difference between synthetic vs plant- or fungus-based medicines</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>12:20 – Conservation considerations for endangered species</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>14:03 – Psychedelics as tools of transformation</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>18:35 – Ibogaine and ethical sourcing of iboga</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>22:05 – Stigma and working in psychedelics</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>25:09 – Psychedelics, back-country skiing, and constructions of risk </li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>27:58 – What is a “medicine”?</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>32:28 – Experience of “natural” vs “synthetic” psychedelic compounds</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>37:06 – Future of psychedelic therapy access</li></ol><br/><p><strong>Guest</strong></p><p>Danny Motyka is the co-founder and Chief Executive Officer of Psygen Industries Ltd., a Calgary-based contract development and manufacturing organization focused on pharmaceutical-grade psychedelic compounds for clinical research and therapeutic use. With an academic background in chemistry and experience in operations and controlled substances regulation, he has positioned Psygen as one of Canada’s leading synthetic psychedelic API manufacturers, aiming to expand global access to evidence-based psychedelic medicines</p><p><strong>Links</strong></p><p><a href="https://psygen.ca" rel="noopener noreferrer" target="_blank">https://psygen.ca</a></p><p><a href="https://therapsil.ca/therapsil-in-loving-memory-of-thomas-hartle/" rel="noopener noreferrer" target="_blank">https://therapsil.ca/therapsil-in-loving-memory-of-thomas-hartle/</a></p><p><a href="https://rootstothrive.com/" rel="noopener noreferrer" target="_blank">https://rootstothrive.com/</a></p><p><strong>Host</strong></p><p>Kenneth Tupper is a public health researcher, drug policy expert, and educator whose work focuses on psychedelics, learning, and wellbeing.</p><p><strong>Disclaimer</strong></p><p>This podcast is for informational and educational purposes only. It does not constitute medical advice. Psychedelics are powerful substances with known risks and are illegal in many jurisdictions. Always consult qualified medical professionals and follow applicable laws.</p>
6 total episodes available
Deep-dive analytics for Intonicated
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Intonicated?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.